摘要
[目的 ]探讨细胞角蛋白 19片段 (CYFRA2 1- 1)检测在肺癌临床诊断中的价值。 [方法 ]采用免疫放射分析法对 70例肺癌患者进行CYFRA2 1- 1含量测定 ,并与 4 0例胸部良性疾病 (BLD)患者 ,4 0例健康人血例健康人进行比较。 [结果 ]肺癌患者血清CYFRA2 1- 1含量为 (4 .6 4± 3.6 8)ng/mL ,胸部良性疾病患者为 (2 .19± 0 .80 )ng/mL(P <0 .0 1) ,健康人为 (1.71± 0 .74 )ng/mL(P<0 .0 1) ,肺癌患者血清CYFRA2 1- 1水平显著高于健康人 ,并且就CYFRA2 1- 1而言 ,NSCLC患者CYFRA2 1- 1水平显著高于小细胞癌 (SCLC)患者 (5 .19± 3.90 )ng/mL和 (3.0 7± 2 .4 2 )ng/mL (P <0 .0 1)。 [结论 ]免疫放射分析法检测血清CYFRA2 1-
Delving into the clinical value of diagnosing lung cancer with section 19 of CYFRA 21-1. Conduct a survey on the content of CYFRA 21-1 with IRMA on 70 lung cancer patients and compare the result with the testing result on 40 BLD patients and 40 healthy people. CYFRA21-1 content in the serum of lung cancer patients is (4.64±3.68) ng/mL,the result on BLD patients is (2.19± 0.80) ng/mL ( P <0.01) for healthy people, the result is (1.71±0.74)ng/mL( P <0.01). The CYFRA21-1 content in the serum of lung cancer patients are all markedly higher than that of healthy individuals, and as far as CYFRA21-1 is concemed, CYFRA21-1 level of NSCLC patients is remarkably higher than SCLC patients (5.19±3.90) ng/mL and (3.07±2.42) ng/mL( P <0.01). [Conclusion] It follows that the testing of CYFRA 21-1 level with IRMA is important in raising the rate of identifying lung cancer and the differential diagnosis of their clinical types.
出处
《大连医科大学学报》
CAS
2003年第1期52-53,共2页
Journal of Dalian Medical University
